Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Safety Study of a 1-year 8 to 24 mg/Day Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder

NCT05648591 is registered in ClinicalTrials.gov with Vanda Pharmaceuticals as lead sponsor.

NCT NCT05648591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05648591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Safety Study of a 1-year 8 to 24 mg/Day Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder
Lead sponsor
Vanda Pharmaceuticals
Phase
Phase 4
Overall status
Recruiting
Start date
May 24, 2023
Completion date
December 31, 2028
Enrollment
100 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder, schizophrenia